COVID-19 Immunisation Programme

NIP Dropbox with downloadable COVID-19 resources and forms for health care professionals can be found here.

‍

The COVID-19 vaccination programme provides all those living in Aotearoa New Zealand with the best protection against the worst outcomes of the COVID-19 disease.

The vaccination programme has evolved over the past few years, with three different versions of the mRNA vaccine Comirnaty now used for most people including those aged 12 years and over as a primary course and additional dose.

An adjuvanted recombinant protein vaccine, Nuvaxovid, is also available for those aged 12 years and over as an alternative primary course and can be used as an additional dose for those aged 18 years or over.

‍

Comirnaty 30mcg XBB.1.5 grey cap vaccine (12+ years)

From 7 March 2024, everyone in Aotearoa New Zealand over the age of 12 years who is not yet vaccinated can receive a single dose of the monovalent Comirnaty Omicron 30mcg XBB.1.5 grey cap vaccine, whether they are eligible for funded health and disability services or not. 

Additional doses are also available to those who are eligible, using this same vaccine. For more information see the IMAC Comirnaty 30mcg XBB.1.5 factsheet. Also see the Manatū Hauora Ministry of Health COVID-19 vaccines webpage and the  Immunisation Handbook for more information. 

‍

Comirnaty 10mcg XBB.1.5 blue cap vaccine (5 to 11 years)

From 30 May 2024, Comirnaty 10mcg XBB.1.5 blue cap vaccine is available for children aged 5 to 11 years and is a lower dose and smaller volume than the grey cap vaccines. It is a single dose vaccine. For more information see the Comirnaty 10mcg XBB.1.5 webpage.

‍

Comirnaty 3mcg XBB.1.5 maroon cap vaccine (6 months to 4 years)

Comirnaty 3mcg XBB.1.5 maroon cap vaccine is limited to young children aged between 6 months and 4 years of age who are at highest risk of severe infection if they were to catch COVID-19, such as those with severe immunocompromise or with complex and/or multiple health conditions.

‍

Nuvaxovid

Pharmac have advised changes to the availability of Novavax’s COVID-19 vaccine (branded Nuvaxovid) from 1 May 2024. The current supply of this vaccine has expired.  

The latest Novavax XBB vaccine application is currently being considered by Medsafe and the assessment is in its final stages. This means there will be no Novovax XBB vaccine available from 1 May 2024 until the new vaccine is approved.

‍

IMAC's latest COVID-19 resources can be found on the right-hand side of each specific vaccine page or within our factsheet resources.  

‍
‍COVID-19 disease
View our information and guidance here.

‍
‍Vaccines

Comirnaty 30mcg XBB.1.5 grey cap vaccine

Comirnaty 10mcg XBB.1.5 blue cap vaccine

Comirnaty 3mcg XBB.1.5 maroon cap vaccine‍

Nuvaxovid vaccine‍

‍

XBB.1.5 webinar recording

View the recording of our recent XBB.1.5 webinar here. This informative webinar covers a range of issues in relation to the new vaccine.

‍

NIP Dropbox with downloadable COVID-19 resources and forms

National Immunisation Programme COVID-19 resources/forms for health care professionals can be found here.

‍

‍

On behalf of Te Whatu Ora, IMAC provides education and training courses for those administering COVID-19 vaccines or otherwise contributing to the programme. The course selection will depend upon the scope of your role.

Different roles and pathways
View information on the different roles in the immunisation workforce here.

COVID-19 programme-specific courses
View IMAC's COVID-19 courses here.

‍